A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
Identifieur interne : 005A03 ( Main/Exploration ); précédent : 005A02; suivant : 005A04A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
Auteurs : John Oxford [Royaume-Uni] ; Shobana Balasingam [Royaume-Uni] ; Rob Lambkin [Royaume-Uni]Source :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2004.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux.
- virologie : Grippe humaine.
- Flambées de maladies, Grippe humaine, Humains, Infections communautaires, Résistance virale aux médicaments.
- Pascal (Inist)
- Wicri :
- topic : Médicament.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Community-Acquired Infections (prevention & control), Disease Outbreaks (prevention & control), Drug, Drug Resistance, Viral, Enzyme Inhibitors (therapeutic use), Exo-α-sialidase, Humans, Influenza, Influenza, Human (drug therapy), Influenza, Human (prevention & control), Influenza, Human (virology), Neuraminidase (antagonists & inhibitors), Use.
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors.
- drug therapy : Influenza, Human.
- prevention & control : Community-Acquired Infections, Disease Outbreaks, Influenza, Human.
- virology : Influenza, Human.
- Drug Resistance, Viral, Humans.
Abstract
Influenza A and B viruses cause serious medical problems and social disruption every year in particular countries of the world. The virus is notoriously fickle and may attack citizens in say two adjacent countries but not the third. More rarely a global pandemic virus emerges causing millions of deaths worldwide. The SARS outbreak has illuminated weaknesses in planning for sudden outbreaks of disease in a modern society and in particular how panic can grip and cause intense economic disruption. Many communities in the world are neither prepared for a global pandemic nor a very acute epidemic of influenza. The neuraminidase inhibitors (NAIs) are a new class of antiviral drug targeting a viral influenza enzyme, the neuraminidase, which acts both to facilitate virus infection of cells by clearing a passage through otherwise protective respiratory fluids and also by helping release of the virus by cutting the chemical umbilical cord which links up the virus to the infected cell. Extensive laboratory studies of the two molecules zanamivir and oseltamivir have shown that they block all influenza A and B viruses yet tested and would, in theory, even inhibit the 1918 pandemic virus. Both drugs can be used prophylactically to prevent spread of infection in families and communities where 80–90% protection has been documented. The therapeutic effects are also strong in adults and children abbreviating infection, reducing quantities of excreted virus and reducing antibiotic prescriptions. The drugs have to be taken within 48 h of the onset of symptoms. Drug resistance is not a problem at present because although such mutants occur the mutants are compromised and are less virulent than their drug-sensitive parents and they spread less easily. The two drugs could be stockpiled to prepare for an influenza pandemic but, importantly, clinical and scientific experience need to be gained by using these inhibitors in the yearly conflagrations of epidemic influenza, which unchecked do great harm to our communities.
Url:
- https://api.istex.fr/ark:/67375/HXZ-35FWKDVR-C/fulltext.pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110053
DOI: 10.1093/jac/dkh037
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000249
- to stream Istex, to step Curation: 000249
- to stream Istex, to step Checkpoint: 002083
- to stream Pmc, to step Corpus: 000B68
- to stream Pmc, to step Curation: 000B68
- to stream Pmc, to step Checkpoint: 001742
- to stream PubMed, to step Corpus: 003029
- to stream PubMed, to step Curation: 003029
- to stream PubMed, to step Checkpoint: 002E60
- to stream Ncbi, to step Merge: 000520
- to stream Ncbi, to step Curation: 000520
- to stream Ncbi, to step Checkpoint: 000520
- to stream Main, to step Merge: 005E50
- to stream PascalFrancis, to step Corpus: 000798
- to stream PascalFrancis, to step Curation: 000192
- to stream PascalFrancis, to step Checkpoint: 000901
- to stream Main, to step Merge: 006052
- to stream Main, to step Curation: 005A03
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community</title><author><name sortKey="Oxford, John" sort="Oxford, John" uniqKey="Oxford J" first="John" last="Oxford">John Oxford</name></author><author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name></author><author><name sortKey="Lambkin, Rob" sort="Lambkin, Rob" uniqKey="Lambkin R" first="Rob" last="Lambkin">Rob Lambkin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9772BC013292A089EFCCAB77A852FF7B0835C69B</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1093/jac/dkh037</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-35FWKDVR-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000249</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000249</idno><idno type="wicri:Area/Istex/Curation">000249</idno><idno type="wicri:Area/Istex/Checkpoint">002083</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002083</idno><idno type="wicri:doubleKey">0305-7453:2004:Oxford J:a:new:millennium</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110053</idno><idno type="RBID">PMC:7110053</idno><idno type="wicri:Area/Pmc/Corpus">000B68</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B68</idno><idno type="wicri:Area/Pmc/Curation">000B68</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000B68</idno><idno type="wicri:Area/Pmc/Checkpoint">001742</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001742</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:14688047</idno><idno type="wicri:Area/PubMed/Corpus">003029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003029</idno><idno type="wicri:Area/PubMed/Curation">003029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003029</idno><idno type="wicri:Area/PubMed/Checkpoint">002E60</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E60</idno><idno type="wicri:Area/Ncbi/Merge">000520</idno><idno type="wicri:Area/Ncbi/Curation">000520</idno><idno type="wicri:Area/Ncbi/Checkpoint">000520</idno><idno type="wicri:doubleKey">0305-7453:2004:Oxford J:a:new:millennium</idno><idno type="wicri:Area/Main/Merge">005E50</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0525181</idno><idno type="wicri:Area/PascalFrancis/Corpus">000798</idno><idno type="wicri:Area/PascalFrancis/Curation">000192</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000901</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000901</idno><idno type="wicri:doubleKey">0305-7453:2004:Oxford J:a:new:millennium</idno><idno type="wicri:Area/Main/Merge">006052</idno><idno type="wicri:Area/Main/Curation">005A03</idno><idno type="wicri:Area/Main/Exploration">005A03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community</title><author><name sortKey="Oxford, John" sort="Oxford, John" uniqKey="Oxford J" first="John" last="Oxford">John Oxford</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea><wicri:noRegion>London E1 4NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea><wicri:noRegion>London E1 4NS</wicri:noRegion></affiliation></author><author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea><wicri:noRegion>London E1 4NS</wicri:noRegion></affiliation></author><author><name sortKey="Lambkin, Rob" sort="Lambkin, Rob" uniqKey="Lambkin R" first="Rob" last="Lambkin">Rob Lambkin</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Barts and The London, Retroscreen Virology Ltd, Queen Mary’s School of Medicine and Dentistry, 327 Mile End Road, London E1 4NS</wicri:regionArea><wicri:noRegion>London E1 4NS</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title><title level="j" type="abbrev">J. Antimicrob. Chemother.</title><idno type="ISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><publisher>Oxford University Press</publisher><date type="published">2004</date><biblScope unit="vol">53</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="133">133</biblScope><biblScope unit="page" to="136">136</biblScope></imprint><idno type="ISSN">0305-7453</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0305-7453</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Community-Acquired Infections (prevention & control)</term><term>Disease Outbreaks (prevention & control)</term><term>Drug</term><term>Drug Resistance, Viral</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Exo-α-sialidase</term><term>Humans</term><term>Influenza</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Use</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Infections communautaires ()</term><term>Résistance virale aux médicaments</term><term>Sialidase (antagonistes et inhibiteurs)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Community-Acquired Infections</term><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Viral</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Infections communautaires</term><term>Résistance virale aux médicaments</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Exo-α-sialidase</term><term>Grippe</term><term>Médicament</term><term>Utilisation</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza A and B viruses cause serious medical problems and social disruption every year in particular countries of the world. The virus is notoriously fickle and may attack citizens in say two adjacent countries but not the third. More rarely a global pandemic virus emerges causing millions of deaths worldwide. The SARS outbreak has illuminated weaknesses in planning for sudden outbreaks of disease in a modern society and in particular how panic can grip and cause intense economic disruption. Many communities in the world are neither prepared for a global pandemic nor a very acute epidemic of influenza. The neuraminidase inhibitors (NAIs) are a new class of antiviral drug targeting a viral influenza enzyme, the neuraminidase, which acts both to facilitate virus infection of cells by clearing a passage through otherwise protective respiratory fluids and also by helping release of the virus by cutting the chemical umbilical cord which links up the virus to the infected cell. Extensive laboratory studies of the two molecules zanamivir and oseltamivir have shown that they block all influenza A and B viruses yet tested and would, in theory, even inhibit the 1918 pandemic virus. Both drugs can be used prophylactically to prevent spread of infection in families and communities where 80–90% protection has been documented. The therapeutic effects are also strong in adults and children abbreviating infection, reducing quantities of excreted virus and reducing antibiotic prescriptions. The drugs have to be taken within 48 h of the onset of symptoms. Drug resistance is not a problem at present because although such mutants occur the mutants are compromised and are less virulent than their drug-sensitive parents and they spread less easily. The two drugs could be stockpiled to prepare for an influenza pandemic but, importantly, clinical and scientific experience need to be gained by using these inhibitors in the yearly conflagrations of epidemic influenza, which unchecked do great harm to our communities.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Oxford, John" sort="Oxford, John" uniqKey="Oxford J" first="John" last="Oxford">John Oxford</name></noRegion><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name><name sortKey="Lambkin, Rob" sort="Lambkin, Rob" uniqKey="Lambkin R" first="Rob" last="Lambkin">Rob Lambkin</name><name sortKey="Oxford, John" sort="Oxford, John" uniqKey="Oxford J" first="John" last="Oxford">John Oxford</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005A03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005A03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9772BC013292A089EFCCAB77A852FF7B0835C69B
|texte= A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
}}
| This area was generated with Dilib version V0.6.33. |  |